Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop

This article was originally published in The Pink Sheet Daily

Executive Summary

The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.

You may also be interested in...



Surprise! It’s A Phase III Failure

When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.

Deals Of The Week: Genentech/Constellation, Bayer/Ventana, Genzyme/Veracyte

Epigenetics took the spotlight this week, with Genentech being the latest pharma to move into the field in partnership with Constellation Pharmaceuticals. In other deals, Bayer signed Ventana to develop a companion diagnostic, and Pfizer walked away from Medivation and Alzheimer’s drug Dimebon.

Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel